Company Overview
Crescent Biopharma, Inc. operates as a biotechnology entity dedicated to researching and developing cancer therapy candidates within the United States, with a primary focus on solid tumors. The company functions within the Healthcare sector and the Biotechnology industry, a space characterized by high research intensity and significant regulatory hurdles before products reach the market. Crescent Biopharma, Inc. holds a market capitalization of $358.66M and reported total annual revenue of $10.84M while employing a workforce of 44 individuals. These financial figures indicate that the company is a small-cap entity operating with limited revenue generation relative to its valuation, suggesting its market position relies heavily on the potential future success of its clinical pipeline rather than current commercial sales. The disparity between its substantial market capitalization and modest revenue highlights the speculative nature of its valuation, which is predicated on the anticipated value of its drug candidates rather than established cash flows.
Financial Health
The company generated revenue of $10.84M over the trailing twelve-month period, yet reported a net income loss of $-153,942,000 and an EBITDA of $-152,548,000. The significant gap between the $10.84M revenue and the $-153,942,000 net income reveals a cost structure where operating expenses vastly exceed revenue, a typical characteristic of biotechnology firms in the development phase. Free cash flow stands at $-153,697,632, indicating that the company is burning through cash reserves to fund its research and development activities rather than generating positive liquidity from operations. The balance sheet shows a cash position of $213.19M against total debt of $1.64M, supported by a debt-to-equity ratio of 0.81. Despite the negative earnings, the company maintains a conservative balance sheet profile as its cash assets significantly outweigh its debt obligations, providing a buffer for ongoing operations. A current ratio of 6.56 demonstrates strong short-term liquidity, meaning the company possesses ample current assets to cover its current liabilities without immediate distress. Return on Equity is recorded at -160.7% and Return on Assets at -69.1%, metrics that reflect the substantial costs incurred by management to generate no profit yet, indicating that management effectiveness in generating returns is currently negative due to the high costs of clinical trials and research.
Valuation Assessment
The trailing P/E ratio is listed as N/A due to the absence of net income, while the forward P/E is -3.29, implying that the market expects earnings to remain negative or that valuation is based on price-to-book metrics given the lack of profitability. The price-to-book ratio is 1.97, indicating that the market values the company at nearly twice its book value, which suggests a premium assigned to the potential value of its intellectual property and pipeline assets despite current losses. The price-to-sales ratio is 33.07 and the EV/EBITDA is -1.20, metrics that suggest the market is valuing the company on a revenue basis rather than earnings, which is common for pre-revenue or loss-making biotech firms. The stock has traded between a 52-week low of $8.72 and a 52-week high of $29.00, and without a specific current share price provided in the data, the position relative to this range remains undefined by the available facts. The beta value is N/A, meaning volatility data relative to the broader market is not available for this specific ticker in the provided dataset. These alternative valuation metrics highlight that traditional earnings-based multiples are not applicable, and investors must rely on revenue and asset-based measures to assess the company's relative worth.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A in the available data, preventing a direct comparison of growth rates between earnings and revenue. As a non-dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, the company does not distribute cash to shareholders, which implies a strategy of reinvesting all available capital, including the $213.19M cash reserve, into research and development to advance its pipeline. The absence of a dividend yield confirms that the company prioritizes funding its clinical trials for CR-001, CR-002, and CR-003 over returning income to investors. The overall growth and income profile is defined by a reliance on future clinical success rather than current earnings growth or dividend income, as the company remains in a development stage with no positive earnings growth to support shareholder distributions.